Business Context and Reporting Period
This Form 8-K was filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on July 23, 2018, reporting events occurring on July 18, 2018. The filing addresses the appointment of Anthony G. Quinn as President and Chief Executive Officer, replacing his prior role as interim CEO, and details his new employment and severance arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms:
- Base Salary: $507,000 annually.
- Target Bonus: 50% of base salary ($253,500).
- Time-Based Stock Option: 300,000 shares at $9.36/share, vesting over 48 months.
- Performance-Based Stock Options: 200,000 shares at $9.36/share, vesting based on board-set objectives.
Material Changes
The primary material change is the formalization of Dr. Quinn's leadership role and the establishment of significant equity and severance obligations. The company granted a total of 500,000 stock options. Certain performance-based grants are contingent upon stockholder approval to increase the share pool under the 2016 Equity Incentive Plan.
Outlook, Risks, and Contingencies
Severance Contingencies: A comprehensive Severance Agreement was executed, providing substantial benefits upon termination without Cause or resignation for Good Reason:
- Change in Control (CIC) Qualifying Termination: 18 months of base salary, 100% of target bonus, 18 months of COBRA premiums, and 100% acceleration of all unvested equity awards.
- Qualifying Termination (Non-CIC): 18 months of base salary, 100% of target bonus, 18 months of COBRA premiums, and acceleration of equity awards as if 12 additional months of vesting had occurred.
Risks: The company faces potential dilution from the issuance of 500,000 new options. The performance-based grants are subject to stockholder approval for plan amendments.
Investor Verification Checklist
- Verify the status of the stockholder vote required to increase the 2016 Equity Incentive Plan share pool.
- Review the specific performance objectives attached to the 200,000 performance-based options.
- Assess the impact of the 500,000 new options on existing shareholder dilution.
- Confirm the total potential cash liability for severance (salary + bonus) in the event of a Change in Control.